东北制药(000597) - 2025 Q3 - 季度财报

Financial Performance - Q3 2025 revenue was CNY 1,625,476,998.14, a decrease of 17.28% year-over-year, and year-to-date revenue was CNY 5,478,085,124.55, down 10.69%[5] - Net profit attributable to shareholders for Q3 2025 was CNY 43,524,470.78, a decline of 14.92% year-over-year, with year-to-date net profit at CNY 172,703,081.21, down 16.96%[5] - Total operating revenue for the current period is ¥5,478,085,124.55, a decrease of 10.7% from ¥6,133,512,515.79 in the previous period[33] - Net profit for the current period is ¥161,044,610.95, a decline of 26.8% compared to ¥220,053,562.43 in the previous period[34] - Earnings per share for the current period is ¥0.1209, down from ¥0.1455 in the previous period[35] Research and Development - R&D expenses for the period amounted to CNY 10,396,000, representing a significant increase of 95% compared to the same period last year[16] - Research and development expenses increased to ¥103,963,842.54, up from ¥53,424,342.80 in the previous period, indicating a focus on innovation[34] - The company received approval for clinical trials of DCTY0801 injection, marking a significant milestone in product development[27] - The company aims to enhance its core competitiveness in the oncology treatment field through accelerated product development[27] Assets and Liabilities - Total assets at the end of the reporting period were CNY 13,648,603,462.73, a decrease of 5.52% from the end of the previous year[5] - Total liabilities amount to ¥8,051,463,190.34, a decrease from ¥8,876,538,951.68 in the previous period[34] - The company’s total assets amount to ¥13,648,603,462.73, down from ¥14,446,181,851.25 in the previous period[34] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 379,202,723.95, a decrease of 11.52%[5] - The net cash inflow from operating activities was CNY 379,202,723.95, a decrease of 11.5% compared to CNY 428,565,749.88 in the previous period[37] - Total cash inflow from financing activities was CNY 9,351,477,799.16, down from CNY 11,004,407,687.50, reflecting a decrease of 15%[38] - The net cash outflow from investment activities was CNY -74,420,303.54, compared to CNY -135,729,071.37 in the previous period, indicating an improvement[37] - Cash received from other operating activities was CNY 173,056,766.13, compared to CNY 223,851,078.74, showing a decline of 22.7%[37] Shareholder Information - Total number of common shareholders at the end of the reporting period is 49,696[26] - Jiangxi Fangda Steel holds 32.08% of shares, totaling 457,861,342 shares[26] - Liaoning Fangda Group holds 23.60% of shares, totaling 329,068,713 shares[26] Inventory and Receivables - Accounts receivable increased to approximately ¥2.25 billion from ¥1.96 billion[30] - Inventory decreased to approximately ¥1.14 billion from ¥1.32 billion[30] - The company's cash and cash equivalents decreased to approximately ¥4.08 billion from ¥4.47 billion[29] Cost Management - Total operating costs for the current period are ¥5,196,594,704.99, down 10.1% from ¥5,783,158,351.88 in the previous period[34] - The company reported a decrease in sales expenses to ¥879,243,019.69 from ¥1,047,384,162.17 in the previous period, reflecting cost control measures[34] - Cash paid for purchasing goods and services was CNY 2,969,341,549.87, down from CNY 3,534,534,806.96, a decrease of 16%[37]